Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer

Mark R Openshaw; David J Pinato; Nicola Valeri

doi:10.1158/1078-0432.CCR-21-0533

Back from the Brink: EGFR Inhibition in Gastroesophageal Cancer

Clin Cancer Res. 2021 Jun 1;27(11):2964-2966. doi: 10.1158/1078-0432.CCR-21-0533. Epub 2021 Mar 26.

Authors

Mark R Openshaw¹, David J Pinato^{1

2}, Nicola Valeri^{3

4

5

6}

Affiliations

¹ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom.
² Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
³ Department of Surgery and Cancer, Faculty of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom. nicola.valeri@icr.ac.uk.
⁴ Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom.
⁵ Department of Medicine, The Royal Marsden NHS Trust, London, United Kingdom.
⁶ Centre for Evolution and Cancer, The Institute of Cancer Research, London, United Kingdom.

PMID: 33771852
DOI: 10.1158/1078-0432.CCR-21-0533

Abstract

Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.See related article by Corso et al., p. 3126.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adenocarcinoma*
ErbB Receptors / genetics
Esophageal Neoplasms* / drug therapy
Humans
Stomach Neoplasms* / drug therapy

Substances

EGFR protein, human
ErbB Receptors

Abstract

Publication types

MeSH terms

Substances

Grants and funding